Gla monotherapy for use in cancer treatment

ABSTRACT

The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.

FIELD

The present disclosure relates generally to compositions and methods fortreating cancer with a glucopyranosyl lipid A (GLA).

BACKGROUND

The innate immune system is an evolutionarily ancient system designed todetect the presence of microbial invaders and activate protectivereactions (Beutler, Mol. Immunol. 2004, 40, 845-859). It respondsrapidly to compounds that are integral parts of pathogens that areperceived as danger signals by the host. Recognition of these molecularpatterns is mediated by sets of highly conserved receptors (vanAmersfoort et al., J. Clin. Microbiol. Rev. 2003, 16, 379), whoseactivation results in acute inflammatory responses. These responsesinclude the production of a diverse set of cytokines and chemokines,directing local attacks against the invading pathogen, and initiation ofresponses that activate and regulate the adaptive component of theimmune system (Dabbagh and Lewis, Curr. Opin. Infect. Dis. 2003, 16,199-204; Bevan, Nat. Rev. Immunol. 2004, 4, 595-602; Pasare andMedzhitov, Seminars Immunol. 2004, 16, 23-26; Finlay and Hancock, Nat.Rev. Microbiol. 2004, 2, 497-504; Akira et al., Nat. Immunol. 2001, 2,675-680; Pasare and Medzhitov, Immunity 2004, 21, 733-741).

Evidence is emerging that innate immune responses can be exploited fortherapeutic purposes such as the development of adjuvants for vaccinesand the treatment of a wide range of diseases including asthma,infections, and cancer. An important concern of such therapies is,however, that over-activation of innate immunity may lead to theclinical symptoms of septic shock (Pittet et al., J. Am. Med. Assoc.1994, 271, 1598-1601; Rice and Bernard, Anna. Rev. Med. 2005, 56,225-248).

It has long been a goal in cancer immunology to enhance immune-mediatedantitumor activity, to achieve tumor regression and improve cancertreatment options. Clearly there is a need for improved compositions andmethods for enhancing anti-tumor immune responses for use as cancertreatments. The present invention provides this and other relatedadvantages.

SUMMARY OF THE INVENTION

One aspect of the present invention provides a method of treating amammal who suffers from cancer, comprising administering an effectiveamount of a composition comprising GLA, said composition comprising:

(a) GLA of the formula:

wherein: R¹, R³, R⁵ and R⁶ are C₁₁-C₂₀ alkyl; and R² and R⁴ are C₁₂-C₂₀alkyl; and

(b) a pharmaceutically acceptable carrier or excipient; wherein thecomposition does not comprise antigen. In one embodiments of the methodsdescribed herein, R¹, R³, R⁵ and R⁶ are undecyl and R² and R⁴ aretridecyl. In another embodiment of the methods described herein, themammal is human. In yet a further embodiment, the composition is anaqueous formulation, and in certain embodiments, the composition is inthe form of an oil-in-water emulsion, a water-in-oil emulsion, liposome,micellar formulation, or a microparticle.

In certain embodiments of the methods described herein, the cancercomprises a solid tumor, and may be a carcinoma, a sarcoma or alymphoma. In another embodiment, the solid tumor is a primary solidtumor or may be a secondary solid tumor. The present methods may be usedfor the treatment of a variety of cancers, including but not limited to,melanoma, Merkel cell carcinoma, non-Hodgkin's lymphoma (NHL), lungcancer, cervical cancer, ovarian cancer, uterine cancer, breast cancer,liver cancer, gastric cancer, prostate cancer, colon cancer, kidneycancer, bladder cancer, brain cancer, and pancreatic cancer.

In certain embodiments, the composition is administered by subcutaneous,intradermal, intramuscular, intratumoral, or intravenous injection. Inadditional embodiments, the composition is administered intranasally orintrapulmonary.

In another embodiment of the methods described herein, the compositionis administered in conjunction with one or more additional therapeuticagents or treatments. In this regard, in certain embodiments, thetherapeutic agent is an anti-cancer agent. The additional therapeuticagents or treatments may be a chemotherapeutic agent, an immunecheckpoint inhibitor, or an antibody that activates a co-stimulatorypathway, such as but not limited to anti-CD40 antibodies. Any of anumber of therapeutic agents is contemplated for use herein, including,but not limited to, taxotere, carboplatin, trastuzumab, epirubicin,cyclophosphamide, carboplatin, cisplatin, docetaxel, doxorubicin,etoposide, 5-FU, gemcitabine, methotrexate, and paclitaxel. In certainembodiments, the one or more additional therapeutic treatments isradiation therapy.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph of tumor size over time in mice administered saline orGLA following injection with B16 melanoma cells.

FIG. 2 is a survival curve showing that mice receiving GLA showedimproved survival rate as compared to mice that received saline alone.

FIG. 3: Development of a murine B16F10 mouse footpad melanoma. B16F10mouse footpad melanoma is a flexible therapeutic tumor model. B16F10tumors are readily observable, therapeutic endpoint is set at tumorvolume <100 mm² and animal health, 0.3E5 B16F10 cells is the recommendedminimal tumor dose, depending on the number of cells injected, thetherapeutic window can range between 14-40 days—Tumor dose cantheoretically be increased to shorten the therapeutic window to lessthan 14 days.

FIG. 4: GLA-SE administered by intramuscular route of administrationsignificantly (p>0.008) modifies the growth kinetics of B16F10 tumorcells in BALB/c mouse. Statistical evaluation was performed using theWilcoxon signed rank test.

FIG. 5: GLA-SE administered by intramuscular route of administrationsignificantly (p>0.03) increases the survival period of BALB/c mousewith B16F10 tumor burden. Statistical analysis was performed using theGehan-Breslow Wilcoxon test.

FIG. 6 is a graph of tumor size over time in mice administered vehicle(2% SE) or GLA-SE intramuscularly (i.m.) or intratumorally (i.t.)following inoculation of tumor cells. Student's t-test was used forinter-group comparisons: *p<0.05.

FIG. 7: Therapeutic Efficacy of GLA+/−a checkpoint inhibitor in theB16F10 mouse melanoma model. A is a graph of tumor size over time intumor-bearing mice administered GLA-SE (i.t.) or 2% SE vehicle controlstarting on Day 4, 9, or 14 post-tumor injection. B is a graph of tumorsize over time in tumor-bearing mice administered GLA-SE (i.t.) or 2% SEvehicle control plus an immune checkpoint inhibitor (anti-PDL1,anti-PD1, anti-CTLA4, or LTF2 control antibody; i.p.) starting on Day 4post-tumor injection. Student's t-test was used for inter-groupcomparisons: *p=0.03; **p=0.005.

FIG. 8: Therapeutic Efficacy of GLA+/−anti-CD40 in the B16F10 mousemelanoma model. A is a graph of tumor size over time in tumor-bearingmice administered GLA-SE (i.t.) or 2% SE vehicle control plus anti-CD40antibody (i.p.) starting on Day 4 post-tumor injection. B is a graph oftumor size over time in tumor-bearing mice administered GLA-SE (i.t.) or2% SE vehicle control on Day 8 and 15 post-tumor injection, plusanti-CD40 (i.t.) on Day 5 and 12 post-tumor injection. Student's t-testwas used for inter-group comparisons: *p=0.03; ns=not significant.

DETAILED DESCRIPTION

The present disclosure relates in part to the surprising observationthat GLA administration alone, given after cancer has been established,resulted in an increase in survival in mice in a B16 melanoma mousemodel. GLA has been used as a vaccine adjuvant to enhance immuneresponses to a variety of antigens. However, prior to the presentapplication, GLA has not been used as a monotherapy for the treatment ofcancer.

As used herein and in the appended claims, the singular forms “a,”“and,” and “the” include plural referents unless the context clearlydictates otherwise. Thus, for example, reference to “an antigen”includes a plurality of such antigens, and reference to “a cell” or “thecell” includes reference to one or more cells and equivalents thereof(e.g., plurality of cells) known to those skilled in the art, and soforth. Similarly, reference to “a compound” or “a composition” includesa plurality of such compounds or compositions, and refers to one or morecompounds or compositions, respectively, unless the context clearlydictates otherwise. When steps of a method are described or claimed, andthe steps are described as occurring in a particular order, thedescription of a first step occurring (or being performed) “prior to”(i.e., before) a second step has the same meaning if rewritten to statethat the second step occurs (or is performed) “subsequent” to the firststep. The term “about” when referring to a number or a numerical rangemeans that the number or numerical range referred to is an approximationwithin experimental variability (or within statistical experimentalerror), and thus the number or numerical range may vary between 1% and15% of the stated number or numerical range. The term “comprising” (andrelated terms such as “comprise” or “comprises” or “having” or“including”) is not intended to exclude that in other certainembodiments, for example, an embodiment of any composition of matter,composition, method, or process, or the like, described herein, may“consist of” or “consist essentially of” the described features.

The methods and compositions herein apply to treatment of any mammal,including humans. Other mammals include small domesticated animals,particularly companion animals and pets, including but not limited to,mice, rats, hamsters, guinea-pigs, rabbits, cats, dogs, and primates.Mammals that may be treated include, for example, non-human primates(e.g., monkey, chimpanzee, gorilla, and the like), rodents (e.g., rats,mice, gerbils, hamsters, ferrets, rabbits), lagomorphs, swine (e.g.,pig, miniature pig), equine, canine, feline, bovine, and other domestic,farm, and zoo animals. Subjects in need of the treatments describedherein have been diagnosed with cancer, or may have signs of ahyperproliferative disorder that renders the subject at risk ofdeveloping cancer. Exemplary cancer conditions are described in furtherdetail herein.

The GLA compounds suitable for use according to the present disclosureinclude any of the following. Without being bound by a theory of theinvention, the GLA compounds described herein are believed to targetTLR4. TLR4 is unique among the TLR family in that downstream signalingoccurs via both the MyD88- and TRIF-dependent pathways. Collectively,these pathways stimulate DC maturation, antigen processing/presentation,T cell priming, and the production of cytokines (e.g., IL-12, IFNα/β,and TNFα) (see, e.g., Iwasaki et al., Nat. Immunol. 5:987 (2004)).

A glucopyranosyl lipid A (GLA) compound of formula (Ia):

or a pharmaceutically acceptable salt thereof, where: R1, R3, R5 and R6are C11-C20 alkyl; and R2 and R4 are C12-C20 alkyl; in a more specificembodiment, the GLA has the formula (Ia) set forth above wherein R1, R3,R5 and R6 are C11-14 alkyl; and R2 and R4 are C12-15 alkyl; in a furthermore specific embodiment, the GLA has the formula (Ia) set forth abovewherein R1, R3, R5 and R6 are C11 alkyl, or undecyl; and R2 and R4 areC13 alkyl, or tridecyl;

or of formula (Ib):

or a pharmaceutically acceptable salt thereof, wherein: L1, L2, L3, L4,L5 and L6 are the same or different and are independently selected fromO, NH, and (CH2); L7, L8, L9 and L10 are the same or different, and atany occurrence may be either absent or C(═O); Y1 is an acid functionalgroup; Y2 and Y3 are the same or different and are each independentlyselected from OH, SH, and an acid functional group; Y4 is OH or SH; R1,R3, R5 and R6 are the same or different and are each independentlyselected from the group of C8-C13 alkyl; and R2 and R4 are the same ordifferent and are each independently selected from the group of C6-C11alkyl.

A DSLP compound is a type of GLA that contains a disaccharide (DS) groupformed by the joining together of two monosaccharide groups selectedfrom glucose and amino substituted glucose, where the disaccharide ischemically bound to both a phosphate (P) group and to a plurality oflipid (L) groups. More specifically, the disaccharide may be visualizedas being formed from two monosaccharide units, each having six carbons.In the disaccharide, one of the monosaccharides will form a reducingend, and the other monosaccharide will form a non-reducing end. Forconvenience, the carbons of the monosaccharide forming the reducingterminus will be denoted as located at positions 1, 2, 3, 4, 5 and 6,while the corresponding carbons of the monosaccharide forming thenon-reducing terminus will be denoted as being located at positions 1′,2′, 3′, 4′, 5′ and 6′, following conventional carbohydrate numberingnomenclature. In the DSLP, the carbon at the 1 position of thenon-reducing terminus is linked, through either an ether (—O—) or amino(—NH—) group, to the carbon at the 6′ position of the reducing terminus.The phosphate group will be linked to the disaccharide, preferablythrough the 4′ carbon of the non-reducing terminus. Each of the lipidgroups will be joined, through either amide (—NH—C(O)—) or ester(—O—C(O)—) linkages to the disaccharide, where the carbonyl group joinsto the lipid group. The disaccharide has 7 positions that may be linkedto an amide or ester group, namely, positions 2′, 3′, and 6′ of thenon-reducing terminus, and positions 1, 2, 3 and 4 of the reducingterminus.

For example, the lipid group has at least three carbons, or at least sixcarbons, preferably at least 8 carbons, and more preferably at least 10carbons, where in each case the lipid group has no more than 24 carbons,no more than 22 carbons, or no more than 20 carbons. In one embodiment,the lipid groups taken together provide 60-100 carbons, preferably 70 to90 carbons. A lipid group may consist solely of carbon and hydrogenatoms, i.e., it may be a hydrocarbyl lipid group, or it may contain onehydroxyl group, i.e., it may be a hydroxyl-substituted lipid group, orit may contain an ester group which is, in turn, joined to a hydrocarbyllipid or a hydroxyl-substituted lipid group through the carbonyl(—C(O)—) of the ester group, i.e., a ester substituted lipid. Ahydrocarbyl lipid group may be saturated or unsaturated, where anunsaturated hydrocarbyl lipid group will have one double bond betweenadjacent carbon atoms.

The DSLP comprises 3, or 4, or 5, or 6 or 7 lipid groups. In one aspect,the DSLP comprises 3 to 7 lipid groups, while in another aspect the DSLPcomprises 4-6 lipids. In one aspect, the lipid group is independentlyselected from hydrocarbyl lipid, hydroxyl-substituted lipid, and estersubstituted lipid. In one aspect, the 1, 4′ and 6′ positions aresubstituted with hydroxyl. In one aspect, the monosaccharide units areeach glucosamine. The DSLP may be in the free acid form, or in the saltform, e.g., an ammonium salt.

In certain embodiments, the lipid on the DSLP is described by thefollowing: the 3′ position is substituted with—O—(CO)—CH2-CH(Ra)(—O—C(O)—Rb); the 2′ position is substituted with—NH—(CO)—CH2-CH(Ra)(—O—C(O)—Rb); the 3 position is substituted with—O—(CO)—CH2-CH(OH)(Ra); the 2 position is substituted with—NH—(CO)—CH2-CH(OH)(Ra); where each of Ra and Rb is selected from decyl,undecyl, dodecyl, tridecyl, tetradecyl, wherein each of these termsrefer to saturated hydrocarbyl groups. In one embodiment, Ra is undecyland Rb is tridecyl, where this compound is described in, for example,U.S. Patent Application Publication 2008/0131466 as “GLA.” The compoundwherein Ra is undecyl and Rb is tridecyl may be used in astereochemically defined form, as available from, for example, AvantiPolar Lipid as PHAD™ adjuvant.

In one aspect, the DSLP is a mixture of naturally-derived compoundsknown as 3D-MPL. 3D-MPL adjuvant is produced commercially in apharmaceutical grade form by GlaxoSmithKline Company as their MPL™adjuvant. 3D-MPL has been extensively described in the scientific andpatent literature, see, e.g., Vaccine Design: the subunit and adjuvantapproach, Powell M. F. and Newman, M. J. eds., Chapter 21 MonophosphorylLipid A as an adjuvant: past experiences and new directions by Ulrich,J. T. and Myers, K. R., Plenum Press, New York (1995) and U.S. Pat. No.4,912,094.

In another aspect, the DSLP compound may be described as comprising (i)a diglucosamine backbone having a reducing terminus glucosamine linkedto a non-reducing terminus glucosamine through an ether linkage betweenhexosamine position 1 of the non-reducing terminus glucosamine andhexosamine position 6 of the reducing terminus glucosamine; (ii) anO-phosphoryl group attached to hexosamine position 4 of the non-reducingterminus glucosamine; and (iii) up to six fatty acyl chains; wherein oneof the fatty acyl chains is attached to 3-hydroxy of the reducingterminus glucosamine through an ester linkage, wherein one of the fattyacyl chains is attached to a 2-amino of the non-reducing terminusglucosamine through an amide linkage and comprises a tetradecanoyl chainlinked to an alkanoyl chain of greater than 12 carbon atoms through anester linkage, and wherein one of the fatty acyl chains is attached to3-hydroxy of the non-reducing terminus glucosamine through an esterlinkage and comprises a tetradecanoyl chain linked to an alkanoyl chainof greater than 12 carbon atoms through an ester linkage. See, e.g.,U.S. Patent Application Publication No. 2008/0131466.

In another aspect, the GLA compound may be a synthetic disaccharidehaving six lipid groups as described in U.S. patent applicationpublication 2010/0310602.

In another aspect, a DSLP is described by chemical formula (II):

wherein the moieties A1 and A2 are independently selected from the groupof hydrogen, phosphate, and phosphate salts. Sodium and potassium areexemplary counterions for the phosphate salts. The moieties R1, R2, R3,R4, R5, and R6 are independently selected from the group of hydrocarbylhaving 3 to 23 carbons, represented by C3-C23. For added clarity it willbe explained that when a moiety is “independently selected from” aspecified group having multiple members, it should be understood thatthe member chosen for the first moiety does not in any way impact orlimit the choice of the member selected for the second moiety. Thecarbon atoms to which R1, R3, R5 and R6 are joined are asymmetric, andthus may exist in either the R or S stereochemistry. In one embodimentall of those carbon atoms are in the R stereochemistry, while in anotherembodiment all of those carbon atoms are in the S stereochemistry.

As used herein, “alkyl” means a straight chain or branched, noncyclic orcyclic, unsaturated or saturated aliphatic hydrocarbon containing from 1to 20 carbon atoms, and in certain preferred embodiments containing from11 to 20 carbon atoms. Representative saturated straight chain alkylsinclude methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, and thelike, including undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl,hexadecyl, heptadecyl, octadecyl, etc.; while saturated branched alkylsinclude isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, and thelike. Representative saturated cyclic alkyls include cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, and the like; while unsaturatedcyclic alkyls include cyclopentenyl and cyclohexenyl, and the like.Cyclic alkyls are also referred to herein as “homocycles” or “homocyclicrings.” Unsaturated alkyls contain at least one double or triple bondbetween adjacent carbon atoms (referred to as an “alkenyl” or “alkynyl”,respectively). Representative straight chain and branched alkenylsinclude ethylenyl, propylenyl, 1-butenyl, 2-butenyl, isobutylenyl,1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl,2,3-dimethyl-2-butenyl, and the like; while representative straightchain and branched alkynyls include acetylenyl, propynyl, 1-butynyl,2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl-1-butynyl, and the like. Forexample, “C18-13 alkyl” and “C6-11 alkyl” mean an alkyl as definedabove, containing from 8-13 or 6-11 carbon atoms, respectively.

As used herein, “acid functional group” means a functional group capableof donating a proton in aqueous media (i.e. a Brønsted-Lowry acid).After donating a proton, the acid functional group becomes a negativelycharged species (i.e. the conjugate base of the acid functional group).Examples of acid functional groups include, but are not limited to:—OP(═O)(OH)₂ (phosphate), —OS(═O)(OH)₂ (sulfate), —OS(OH)₂ (sulfite),—OC(OH)₂ (carboxylate), —OC(═O)CH(NH₂)CH₂C(═O)OH (aspartate),—OC(═O)CH₂CH₂C(═O)OH (succinate), and —OC(═O)CH₂OP(═O)(OH)₂(carboxymethylphosphate).

As used herein, “hydrocarbyl” refers to a chemical moiety formedentirely from hydrogen and carbon, where the arrangement of the carbonatoms may be straight chain or branched, noncyclic or cyclic, and thebonding between adjacent carbon atoms may be entirely single bonds, thatis, to provide a saturated hydrocarbyl, or there may be double or triplebonds present between any two adjacent carbon atoms, i.e., to provide anunsaturated hydrocarbyl, and the number of carbon atoms in thehydrocarbyl group is between 3 and 24 carbon atoms. The hydrocarbyl maybe an alkyl, where representative straight chain alkyls include methyl,ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, and the like, includingundecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl,heptadecyl, octadecyl, etc.; while branched alkyls include isopropyl,sec-butyl, isobutyl, tert-butyl, isopentyl, and the like. Representativesaturated cyclic hydrocarbyls include cyclopropyl, cyclobutyl,cyclopentyl, cyclohexyl, and the like; while unsaturated cyclichydrocarbyls include cyclopentenyl and cyclohexenyl, and the like.Unsaturated hydrocarbyls contain at least one double or triple bondbetween adjacent carbon atoms (referred to as an “alkenyl” or “alkynyl,”respectively, if the hydrocarbyl is non-cyclic, and cycloalkeny andcycloalkynyl, respectively, if the hydrocarbyl is at least partiallycyclic). Representative straight chain and branched alkenyls includeethylenyl, propylenyl, 1-butenyl, 2-butenyl, isobutylenyl, 1-pentenyl,2-pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl,2,3-dimethyl-2-butenyl, and the like; while representative straightchain and branched alkynyls include acetylenyl, propynyl, 1-butynyl,2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl-1-butynyl, and the like.

The compound of formula (II) may be obtained by synthetic methods knownin the art, for example, the synthetic methodology disclosed in PCTInternational Publication No. WO 2009/035528, which is incorporatedherein by reference, as well as the publications identified in WO2009/035528, each of which publications is also incorporated herein byreference. Certain of these compounds may also be obtained commercially.

The DSLP compound may be obtained by synthetic methods known in the art,for example, the synthetic methodology disclosed in PCT InternationalPublication No. WO 2009/035528, which is incorporated herein byreference, as well as the publications identified in WO 2009/035528,where each of those publications is also incorporated herein byreference. A chemically synthesized DSLP compound, e.g., the compound offormula (II), can be prepared in substantially homogeneous form, whichrefers to a preparation that is at least 80%, at least 85%, at least90%, at least 95% or at least 96%, 97%, 98% or 99% pure with respect tothe DSLP molecules present, e.g., the compounds of formula (II).Determination of the degree of purity of a given preparation can bereadily made by those familiar with the appropriate analytical chemistrymethodologies, such as by gas chromatography, liquid chromatography,mass spectroscopy and/or nuclear magnetic resonance analysis. DSLPcompounds obtained from natural sources are typically not easily made ina chemically pure form, and thus synthetically prepared compounds arepreferred for use in the compositions and methods for treating cnacerdescribed herein. As discussed previously, certain of the DSLP compoundsmay be obtained commercially. One such DSLP compound is Product No.699800 as identified in the catalog of Avanti Polar Lipids, AlabasterAL, see E1 in combination with E10, below.

In various embodiments, the compound has the chemical structure offormula (II) but the moieties A1, A2, R1, R2, R3, R4, R5, and R6 areselected from subsets of the options previously provided for thesemoieties, wherein these subsets are identified below by E1, E2, etc.

E1: A1 is phosphate or phosphate salt and A2 is hydrogen.

E2: R1, R3, R5 and R6 are C3-C21 alkyl; and R2 and R4 are C5-C23hydrocarbyl.

E3: R1, R3, R5 and R6 are C5-C17 alkyl; and R2 and R4 are C7-C19hydrocarbyl.

E4: R1, R3, R5 and R6 are C7-C15 alkyl; and R2 and R4 are C9-C17hydrocarbyl.

E5: R1, R3, R5 and R6 are C9-C13 alkyl; and R2 and R4 are C11-C15hydrocarbyl.

E6: R1, R3, R5 and R6 are C9-C15 alkyl; and R2 and R4 are C11-C17hydrocarbyl.

E7: R1, R3, R5 and R6 are C7-C13 alkyl; and R2 and R4 are C9-C15hydrocarbyl.

E8: R1, R3, R5 and R6 are C11-C20 alkyl; and R2 and R4 are C12-C20hydrocarbyl.

E9: R1, R3, R5 and R6 are C11 alkyl; and R2 and R4 are C13 hydrocarbyl.

E10: R1, R3, R5 and R6 are undecyl and R2 and R4 are tridecyl.

In certain embodiments, each of E2 through E10 is combined withembodiment E1, and/or the hydrocarbyl groups of E2 through E9 are alkylgroups, preferably straight chain alkyl groups.

U.S. Patent Publication No. 2008/0131466 that provides formulations,such as aqueous formulation (AF) and stable emulsion formulations (SE)for GLA compounds, wherein these formulations may be used for any of thecompounds of formula (I).

The invention provides compositions for stimulating an immune responsein a cancer patient. Typically, immune responses may be detected by anyof a variety of well-known parameters, including but not limited to invivo or in vitro determination of: soluble immunoglobulins orantibodies; soluble mediators such as cytokines, lymphokines,chemokines, hormones, growth factors and the like as well as othersoluble small peptide, carbohydrate, nucleotide and/or lipid mediators;cellular activation state changes as determined by altered functional orstructural properties of cells of the immune system, for example cellproliferation, altered motility, induction of specialized activitiessuch as specific gene expression or cytolytic behavior; cellulardifferentiation by cells of the immune system, including altered surfaceantigen expression profiles or the onset of apoptosis (programmed celldeath); an increase in cytotoxic T-cells, activated macrophages ornatural killer cells; or any other criterion by which the presence of animmune response may be detected.

Procedures for performing these and similar assays are widely known andmay be found, for example in Lefkovits (Immunology Methods Manual: TheComprehensive Sourcebook of Techniques, 1998; see also Current Protocolsin Immunology; see also, e.g., Weir, Handbook of ExperimentalImmunology, 1986 Blackwell Scientific, Boston, Mass.; Mishell and Shigii(eds.) Selected Methods in Cellular Immunology, 1979 Freeman Publishing,San Francisco, Calif.; Green and Reed, 1998 Science 281:1309 andreferences cited therein.).

Detection of the proliferation of tumor-reactive T cells may beaccomplished by a variety of known techniques. For example, T cellproliferation can be detected by measuring the rate of DNA synthesis,and tumor specificity can be determined by controlling the stimuli (suchas, for example, a specific desired tumor- or a control antigen-pulsedantigen presenting cells) to which candidate tumor-reactive T cells areexposed. T cells which have been stimulated to proliferate exhibit anincreased rate of DNA synthesis. A typical way to measure the rate ofDNA synthesis is, for example, by pulse-labeling cultures of T cellswith tritiated thymidine, a nucleoside precursor which is incorporatedinto newly synthesized DNA. The amount of tritiated thymidineincorporated can be determined using a liquid scintillationspectrophotometer. Other ways to detect T cell proliferation includemeasuring increases in interleukin-2 (IL-2) production, Ca²⁺ flux, ordye uptake, such as3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium Alternatively,synthesis of lymphokines (such as interferon-gamma) can be measured orthe relative number of T cells that can respond to a particular antigenmay be quantified.

Detection of antibody production (e.g., tumor specific antibodyproduction) may be achieved, for example, by assaying a sample (e.g., animmunoglobulin containing sample such as serum, plasma or blood) from ahost treated with a GLA composition according to the present inventionusing in vitro methodologies such as radioimmunoassay (RIA), enzymelinked immunosorbent assays (ELISA), equilibrium dialysis or solid phaseimmunoblotting including Western blotting. In preferred embodimentsELISA assays may further include tumor antigen-capture immobilization ofa target tumor antigen with a solid phase monoclonal antibody specificfor the antigen, for example, to enhance the sensitivity of the assay.Elaboration of soluble mediators (e.g., cytokines, chemokines,lymphokines, prostaglandins, etc.) may also be readily determined byenzyme-linked immunosorbent assay (ELISA), for example, using methods,apparatus and reagents that are readily available from commercialsources (e.g., Sigma, St. Louis, Mo.; see also R & D Systems 2006Catalog, R & D Systems, Minneapolis, Minn.).

Any number of other immunological parameters may be monitored usingroutine assays that are well known in the art. These may include, forexample, antibody dependent cell-mediated cytotoxicity (ADCC) assays,secondary in vitro antibody responses, flow immunocytofluorimetricanalysis of various peripheral blood or lymphoid mononuclear cellsubpopulations using well established marker antigen systems,immunohistochemistry or other relevant assays. These and other assaysmay be found, for example, in Rose et al. (Eds.), Manual of ClinicalLaboratory Immunology, 5^(th) Ed., 1997 American Society ofMicrobiology, Washington, D.C.

Accordingly it is contemplated that the GLA compositions provided hereinwill be capable of eliciting or enhancing in a cancer patient at leastone immune response that is selected from a T_(H)1-type T lymphocyteresponse, a T_(H)2-type T lymphocyte response, a cytotoxic T lymphocyte(CTL) response, an antibody response, a cytokine response, a lymphokineresponse, a chemokine response, and an inflammatory response. In certainembodiments, the immune response may include suppression of regulatory Tcells, such as a decrease in the number of CD4+FoxP3+ T regulatorycells. In another embodiment, the immune response comprises an increasein the number of intratumoral CD8+ T effector cells. In certainembodiments the immune response may comprise at least one of productionof one or a plurality of cytokines wherein the cytokine is selected frominterferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α),production of one or a plurality of interleukins wherein the interleukinis selected from IL-1, IL-2, IL-3, IL-4, IL-6, IL-8, IL-10, IL-12,IL-13, IL-16, IL-18 and IL-23, production of one or a plurality ofchemokines wherein the chemokine is selected from MIP-1α, MIP-1β,RANTES, CCL4 and CCLS, and a lymphocyte response that is selected from amemory T cell response, a memory B cell response, an effector T cellresponse, a cytotoxic T cell response and an effector B cell response.See, e.g., WO 94/00153; WO 95/17209; WO 96/02555; U.S. Pat. No.6,692,752; U.S. Pat. No. 7,084,256; U.S. Pat. No. 6,977,073; U.S. Pat.No. 6,749,856; U.S. Pat. No. 6,733,763; U.S. Pat. No. 6,797,276; U.S.Pat. No. 6,752,995; U.S. Pat. No. 6,057,427; U.S. Pat. No. 6,472,515;U.S. Pat. No. 6,309,847; U.S. Pat. No. 6,969,704; U.S. Pat. No.6,120,769; U.S. Pat. No. 5,993,800; U.S. Pat. No. 5,595,888; Smith etal., 1987 J Biol. Chem. 262:6951; Kriegler et al., 1988 Cell 53:4553;Beutler et al., 1986 Nature 320:584; U.S. Pat. No. 6,991,791; U.S.Pat. No. 6,654,462; U.S. Pat. No. 6,375,944.

Pharmaceutical Compositions, Delivery and Methods of Use

In examples of embodiments, the GLA compounds described herein arepresent in a composition in an amount of 0.1-10 μg/dose, or 0.1-20μg/dose, 0.1-30 μg/dose, 0.1-40 μg/dose, or 0.1-50 μg/dose, or 1-20μg/dose, or 1-30 μg/dose, or 1-40 μg/dose, or 1-50 μg/dose, or 0.2-5μg/dose, or in an amount of 0.5-2.5 μg/dose, or in an amount of 0.5-8μg/dose or 0.5-15 μg/dose. Doses may be, for example, 0.5 μg/dose, 0.6μg/dose, 0.7 μg/dose, 0.8 μg/dose, 0.9 μg/dose, 1.0 μg/dose, 2.0μg/dose, 3.0 μg/dose, 3.5 μg/dose, 4.0 μg/dose, 4.5 μg/dose, 5.0μg/dose, 5.5 μg/dose, 6.0 μg/dose, 6.5 μg/dose, 7.0 μg/dose, 7.5μg/dose, 8.0 μg/dose, 9.0 μg/dose, 10.0 μg/dose, 11.0 μg/dose, 12.0μg/dose, 13.0 μg/dose, 14.0 μg/dose, or 15.0 μg/dose. Doses may beadjusted depending upon the body mass, body area, weight, blood volumeof the subject, or route of delivery. In one embodiment, 2 μg, 3 μg, 4μg, 5 μg, 6 μg, 7 μg, 8 μg, 9 μg, 10 μg, 11 μg, or 12 μg of GLA in 1 mlis administered intratumorally. In this regard, the 1 mL dose of GLA maybe injected in equal amounts in multiple zones of the tumor. In certainembodiments, about 0.01 μg/kg to about 100 mg/kg body weight of GLA willbe administered, typically by the intradermal, intratumoral,subcutaneous, intramuscular or intravenous route, or by other routes. Incertain embodiments, the dosage of GLA is about 0.1 μg/kg to about 1mg/kg, and in certain embodiments, ranges from about 0.1 μg/kg, 0.2μg/kg, 0.3 μg/kg, 0.4 μg/kg, 0.5 μg/kg, 0.6 μg/kg, 0.7 μg/kg, 0.8 μg/kg,0.9 μg/kg, 1 μg/kg, 2 μg/kg, 3 μg/kg, 4 μg/kg, 5 μg/kg, 6 μg/kg, 7μg/kg, 8 μg/kg, 9 μg/kg, 10 μg/kg to about 200 μg/kg. It will be evidentto those skilled in the art that the number and frequency ofadministration will be dependent upon the response of the host. Asdescribed herein, the appropriate dose may also depend upon thepatient's (e.g., human) condition, that is, stage of the disease,general health status, as well as age, gender, and weight, and otherfactors familiar to a person skilled in the medical art. As notedelsewhere herein, the GLA compositions described herein do not includeantigen.

Pharmaceutical compositions may be formulated for any appropriate mannerof administration, including, for example, topical, oral, enteral, nasal(i.e., intranasal), inhalation, intrathecal, rectal, vaginal,intraocular, subconjunctival, buccal, sublingual, intrapulmonary,intradermal, intranodal, intratumoral, transdermal, or parenteraladministration, including subcutaneous, percutaneous, intravenous,intramuscular, intrasternal, intracavernous, intrameatal, intratumoral,intracranial, intraspinal or intraurethral injection or infusion.Methods of administration are described in greater detail herein.

Compositions comprising a GLA as described herein and optionally furthercomprising one or more additional therapeutic agents, may be formulatedfor delivery by any route that provides an effective dose of the GLA orthe one or more additional therapeutic agents. Such administrationsmethods include oral administration or delivery by injection and may bein the form of a liquid. A liquid pharmaceutical composition mayinclude, for example, one or more of the following: a sterile diluentsuch as water for injection, saline solution, preferably physiologicalsaline, Ringer's solution, isotonic sodium chloride, fixed oils that mayserve as the solvent or suspending medium, polyethylene glycols,glycerin, propylene glycol or other solvents; antibacterial agents;antioxidants; chelating agents; buffers and agents for the adjustment oftonicity such as sodium chloride or dextrose. A parenteral preparationcan be enclosed in ampoules, disposable syringes or multiple dose vialsmade of glass or plastic. The use of physiological saline is preferred,and an injectable pharmaceutical composition is preferably sterile.

The GLA composition may further comprise at least one physiologically(or pharmaceutically) acceptable or suitable excipient. Anyphysiologically or pharmaceutically suitable excipient or carrier (i.e.,a non-toxic material that does not interfere with the activity of theactive ingredient) known to those of ordinary skill in the art for usein pharmaceutical compositions may be employed in the compositionsdescribed herein. Exemplary excipients include diluents and carriersthat maintain stability and integrity of proteins. Excipients fortherapeutic use are well known, and are described, for example, inRemington: The Science and Practice of Pharmacy (Gennaro, 21st Ed. MackPub. Co., Easton, Pa. (2005)), and are described in greater detailherein.

“Pharmaceutically acceptable carriers” for therapeutic use are wellknown in the pharmaceutical art, and are described, for example, inRemingtons Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaroedit. 1985). For example, sterile saline and phosphate buffered salineat physiological pH may be used. Preservatives, stabilizers, dyes andeven flavoring agents may be provided in the pharmaceutical composition.For example, sodium benzoate, sorbic acid and esters of p hydroxybenzoicacid may be added as preservatives. Id. at 1449. In addition,antioxidants and suspending agents may be used. Id.

“Pharmaceutically acceptable salt” refers to salts of the compounds ofthe present invention derived from the combination of such compounds andan organic or inorganic acid (acid addition salts) or an organic orinorganic base (base addition salts). The compositions of the presentinvention may be used in either the free base or salt forms, with bothforms being considered as being within the scope of the presentinvention.

The pharmaceutical compositions may be in any form which allows for thecomposition to be administered to a patient. For example, thecomposition may be in the form of a solid, liquid or gas (aerosol). Thepharmaceutical compositions may be administered by any route. Typicalroutes of administration include, without limitation, oral, sublingual,buccal, topical, parenteral, rectal, vaginal, intranasal (e.g., as aspray) and intrapulmonary administration. The term parenteral as usedherein includes iontophoretic (e.g., U.S. Pat. Nos. 7,033,598;7,018,345; 6,970,739), sonophoretic (e.g., U.S. Pat. Nos. 4,780,212;4,767,402; 4,948,587; 5,618,275; 5,656,016; 5,722,397; 6,322,532;6,018,678), thermal (e.g., U.S. Pat. Nos. 5,885,211; 6,685,699), passivetransdermal (e.g., U.S. Pat. Nos. 3,598,122; 3,598,123; 4,286,592;4,314,557; 4,379,454; 4,568,343; 5,464,387; UK Pat. Spec. No. 2232892;U.S. Pat. Nos. 6,871,477; 6,974,588; 6,676,961), microneedle (e.g., U.S.Pat. Nos. 6,908,453; 5,457,041; 5,591,139; 6,033,928) administration andalso subcutaneous injections, intravenous, intramuscular, intrasternal,intracavernous, intrathecal, intranodal, intrameatal, intraurethral,intratumoral injection or infusion techniques. In a particularembodiment, a composition as described herein is administeredintradermally by a technique selected from iontophoresis,microcavitation, sonophoresis or microneedles.

The pharmaceutical composition is formulated so as to allow the activeingredients contained therein to be bioavailable upon administration ofthe composition to a patient. Compositions that will be administered toa patient take the form of one or more dosage units, where for example,a tablet may be a single dosage unit, and a container of one or morecompounds of the invention in aerosol form may hold a plurality ofdosage units.

For oral administration, an excipient and/or binder may be present.Examples are sucrose, kaolin, glycerin, starch dextrins, sodiumalginate, carboxymethylcellulose and ethyl cellulose. Coloring and/orflavoring agents may be present. A coating shell may be employed.

The composition may be in the form of a liquid, e.g., an elixir, syrup,solution, emulsion or suspension. The liquid may be for oraladministration or for delivery by injection, as two examples. Whenintended for oral administration, preferred compositions contain one ormore of a sweetening agent, preservatives, dye/colorant and flavorenhancer. In a composition intended to be administered by injection, oneor more of a surfactant, preservative, wetting agent, dispersing agent,suspending agent, buffer, stabilizer and isotonic agent may be included.

A liquid pharmaceutical composition as used herein, whether in the formof a solution, suspension or other like form, may include one or more ofthe following carriers or excipients: sterile diluents such as water forinjection, saline solution, preferably physiological saline, Ringer'ssolution, isotonic sodium chloride, fixed oils such as squalene,squalane, mineral oil, a mannide monooleate, cholesterol, and/orsynthetic mono or digylcerides which may serve as the solvent orsuspending medium, polyethylene glycols, glycerin, propylene glycol orother solvents; antibacterial agents such as benzyl alcohol or methylparaben; antioxidants such as ascorbic acid or sodium bisulfite;chelating agents such as ethylenediaminetetraacetic acid; buffers suchas acetates, citrates or phosphates and agents for the adjustment oftonicity such as sodium chloride or dextrose. The parenteral preparationcan be enclosed in ampoules, disposable syringes or multiple dose vialsmade of glass or plastic. An injectable pharmaceutical composition ispreferably sterile.

In a particular embodiment, a composition of the invention comprises astable aqueous suspension of less than 0.2 um and further comprises atleast one component selected from the group consisting of phospholipids,fatty acids, surfactants, detergents, saponins, fluorodated lipids, andthe like. Such a stable aqueous formulation may be a micellarformulation.

In another embodiment, a composition of the invention is formulated in amanner which can be aerosolized, either as a powder or liquidformulation.

It may also be desirable to include other components in a pharmaceuticalcomposition, such as including but not limited to water-in-oilemulsions, biodegradable oil vehicles, oil-in-water emulsions,liposomes, micellar components, microparticles, biodegradablemicrocapsules, and liposomes.

In certain embodiments, the GLA compositions are formulated as describedin U.S. Pat. Nos. 8,273,361; 8343,512; or as described in publishedinternational applications WO2008/153541; WO2009/143457, with theexception being that in the present invention no antigen is included.Other suitable formulations are described in WO2013/119856, againwithout including any antigen.

In specific embodiments, compositions comprising GLA as described hereincomprise a stable oil-in-water emulsion and a metabolizable oil. In aparticular embodiment, a composition of the invention comprises anemulsion of oil in water wherein the GLA is incorporated in the oilphase. In certain embodiments, the oil phase of the emulsion comprises ametabolizable oil. The meaning of the term metabolizable oil is wellknown in the art. Metabolizable can be defined as “being capable ofbeing transformed by metabolism” (Dorland's illustrated MedicalDictionary, W. B. Saunders Company, 25th edition (1974)). The oil may beany plant oil, vegetable oil, fish oil, animal oil or synthetic oil,which is not toxic to the recipient and is capable of being transformedby metabolism. Nuts (such as peanut oil), seeds, and grains are commonsources of vegetable oils. Synthetic oils may also be used.

In certain embodiments, additional immunostimulatory substances may beincluded in the compositions described herein and may includeN-acetylmuramyl-L-alanine-D-isoglutamine (MDP), glucan, IL 12, GM CSF,interferon-γ and IL 12.

While any suitable carrier known to those of ordinary skill in the artmay be employed in the pharmaceutical compositions of this invention,the type of carrier will vary depending on the mode of administrationand whether a sustained release is desired. For parenteraladministration, such as subcutaneous injection, the carrier preferablycomprises water, saline, alcohol, a fat, a wax or a buffer. For oraladministration, any of the above carriers or a solid carrier, such asmannitol, lactose, starch, magnesium stearate, sodium saccharine,talcum, cellulose, glucose, sucrose, and magnesium carbonate, may beemployed. Biodegradable microspheres (e.g., polylactic galactide) mayalso be employed as carriers for the pharmaceutical compositions of thisinvention. Suitable biodegradable microspheres are disclosed, forexample, in U.S. Pat. Nos. 4,897,268 and 5,075,109. In this regard, itis preferable that the microsphere be larger than approximately 25microns.

Compositions comprising GLA may also contain diluents such as buffers,antioxidants such as ascorbic acid, carbohydrates including glucose,sucrose or dextrins, chelating agents such as EDTA, glutathione andother stabilizers and excipients. Neutral buffered saline or salinemixed with nonspecific serum albumin are exemplary appropriate diluents.Preferably, product may be formulated as a lyophilizate usingappropriate excipient solutions (e.g., sucrose) as diluents.

The GLA compositions may be intended for topical administration, inwhich case the carrier may suitably comprise a solution, emulsion,ointment or gel base. The base, for example, may comprise one or more ofthe following: petrolatum, lanolin, polyethylene glycols, beeswax,mineral oil, diluents such as water and alcohol, and emulsifiers andstabilizers. Thickening agents may be present in a pharmaceuticalcomposition for topical administration. If intended for transdermaladministration, the composition may include a transdermal patch oriontophoresis device.

The compositions provided herein can be in various forms, e.g., insolid, liquid, powder, aqueous, or lyophilized form.

Compositions comprising a GLA as described herein may also beadministered simultaneously with, prior to, or after administration ofone or more other therapeutic agents. In this regard, the one or moreadditional therapeutic agents does not include antigen, e.g., a tumorantigen. Thus, the GLA compositions described herein may comprise othertherapeutic agents and/or acceptable carriers or excipients but thecompositions do not comprise and are not administered in conjunctionwith antigen. To the extent GLA compositions as described herein areformulated with one or more therapeutic agents, carriers or excipients,such formulated compositions do not comprise an antigen (e.g., anantigen is not added as a component of the formulation).

Such combination therapy may include administration of a singlepharmaceutical dosage formulation which contains a GLA and one or moreadditional active agents, as well as administration of compositionscomprising a GLA of the invention and each active agent in its ownseparate pharmaceutical dosage formulation. For example, a compositioncomprising a GLA and the other active agent can be administered to thepatient together in a single enteral (e.g., oral) dosage compositionsuch as a tablet or capsule, or each agent administered in separateenteral (e.g., oral) dosage formulations. Similarly, compositionscomprising a GLA and the other active agent can be administered to thepatient together in a single parenteral (e.g., any of the parenteralroutes known and described herein, such as, subcutaneous, intradermal,intranodal, intratumoral or intramuscular) dosage composition such as ina saline solution or other physiologically acceptable solution, or eachagent administered in separate parenteral dosage formulations. Thecombination therapies as described herein can be administered by thesame route or may be administered using different routes (e.g.,intratumoral GLA injection combined with intratumoral injection of oneor more other therapeutic agents; or intratumoral GLA injection combinedwith intramuscular, intravenous, subcutaneous or other route ofadministration of one or more other therapeutic agents; any combinationof administration route is contemplated for use with the combinationtherapies described herein). Where separate dosage formulations areused, the compositions comprising a GLA and one or more additionalactive agents can be administered at essentially the same time, i.e.,concurrently, or at separately staggered times, i.e., sequentially andin any order; combination therapy is understood to include all theseregimens.

Thus, in certain embodiments, also contemplated is the administration ofcompositions comprising a GLA of this disclosure in combination with oneor more other therapeutic agents (e.g. other anti-cancer agents, orother palliative or adjunctive therapy). In certain embodiments, suchtherapeutic agents may be accepted in the art as a standard treatmentfor a particular cancer as described herein. Exemplary therapeuticagents contemplated include cytokines, growth factors, steroids, NSAIDs,DMARDs, anti-inflammatories, immune checkpoint inhibitors,chemotherapeutics, radiotherapeutics, or other active and ancillaryagents.

In one embodiment, compositions comprising a GLA are administered incombination with one or more cancer therapeutic agents, including one ormore chemotherapeutic agents. Examples of cancer therapeutic agentsinclude alkylating agents such as thiotepa and cyclophosphamide(CYTOXAN); alkyl sulfonates such as busulfan, improsulfan andpiposulfan; aziridines such as benzodopa, carboquone, meturedopa, anduredopa; ethylenimines and methylamelamines including altretamine,triethylenemelamine, trietylenephosphoramide,triethylenethiophosphaoramide and trimethylolomelamine; nitrogenmustards such as chlorambucil, chlornaphazine, cholophosphamide,estramustine, ifosfamide, mechlorethamine, mechlorethamine oxidehydrochloride, melphalan, novembichin, phenesterine, prednimustine,trofosfamide, uracil mustard; nitrosureas such as carmustine,chlorozotocin, fotemustine, lomustine, nimustine, ranimustine;antibiotics such as aclacinomysins, actinomycin, authramycin, azaserine,bleomycins, cactinomycin, calicheamicin, carabicin, caminomycin,carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin,6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin,idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin,olivomycins, peplomycin, potfiromycin, puromycin, quelamycin,rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex,zinostatin, zorubicin; anti-metabolites such as methotrexate and5-fluorouracil (5-FU); folic acid analogues such as denopterin,methotrexate, pteropterin, trimetrexate; purine analogs such asfludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidineanalogs such as ancitabine, azacitidine, 6-azauridine, carmofur,cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine,5-FU; androgens such as calusterone, dromostanolone propionate,epitiostanol, mepitiostane, testolactone; anti-adrenals such asaminoglutethimide, mitotane, trilostane; folic acid replenisher such asfrolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinicacid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine;demecolcine; diaziquone; elformithine; elliptinium acetate; etoglucid;gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone;mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin;podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK®; razoxane;sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2′,2″-trichlorotriethylamine; urethan; vindesine; dacarbazine;mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine;arabinoside (“Ara-C”); cyclophosphamide; thiotepa; taxoids, e.g.paclitaxel (TAXOL®, Bristol-Myers Squibb Oncology, Princeton, N.J.) anddoxetaxel (TAXOTERE®, Rhne-Poulenc Rorer, Antony, France); chlorambucil;gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinumanalogs such as cisplatin and carboplatin; vinblastine; trastuzumab,docetaxel, platinum; etoposide (VP-16); ifosfamide; mitomycin C;mitoxantrone; vincristine; vinorelbine; navelbine; novantrone;teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11;topoisomerase inhibitor RFS 2000; difluoromethylomithine (DMFO);retinoic acid derivatives such asTargretin™ (bexarotene), Panretin™(alitretinoin); ONTAKT™ (denileukin diftitox); esperamicins;capecitabine; and pharmaceutically acceptable salts, acids orderivatives of any of the above. Also included in this definition areanti-hormonal agents that act to regulate or inhibit hormone action ontumors such as anti-estrogens including for example tamoxifen,raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen,trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston);and anti-androgens such as flutamide, nilutamide, bicalutamide,leuprolide, and goserelin; and pharmaceutically acceptable salts, acidsor derivatives of any of the above. Further cancer therapeutic agentsinclude sorafenib and other protein kinase inhibitors such as afatinib,axitinib, bevacizumab, cetuximab, crizotinib, dasatinib, erlotinib,fostamatinib, gefitinib, imatinib, lapatinib, lenvatinib, mubritinib,nilotinib, panitumumab, pazopanib, pegaptanib, ranibizumab, ruxolitinib,trastuzumab, vandetanib, vemurafenib, and sunitinib; sirolimus(rapamycin), everolimus and other mTOR inhibitors.

In another embodiment, the GLA compositions herein are administered incombination with another immunostimulatory agent. Such immunostimulatoryagents include, but are not limited to,N-acetylmuramyl-L-alanine-D-isoglutamine (MDP), glucan, IL-12, GM-CSF,interferon-γ and anti-CD40 antibodies or other antibodies that bind toand activate co-stimulatory pathways (e.g., CD28, ICOS, OX40, CD27 andthe like).

In one embodiment, the GLA compositions herein are administered incombination with one or more immune checkpoint inhibitors. Immunecheckpoints refer to a variety of inhibitory pathways of the immunesystem that are crucial for maintaining self-tolerance and formodulating the duration and amplitude of an immune responses. Tumors usecertain immune-checkpoint pathways as a major mechanism of immuneresistance, particularly against T cells that are specific for tumorantigens. (see, e.g., Pardoll, 2012 Nature 12:252; Chen and Mellman 2013Immunity 39:1). The present disclosure provides immune checkpointinhibitors that can be administered in combination with the GLAcompositions without antigen. Such combination therapies work in concertto enhance an anti-cancer immune response. Certain viruses have alsodeveloped mechanisms to co-opt immune checkpoint pathways. Therefore, incertain embodiments, such combination therapy may be used to enhance ananti-viral immune response.

Immune checkpoint inhibitors include any agent that blocks or inhibitsin a statistically significant manner, the inhibitory pathways of theimmune system. Such inhibitors may include small molecule inhibitors ormay include antibodies, or antigen binding fragments thereof, that bindto and block or inhibit immune checkpoint receptors or antibodies thatbind to and block or inhibit immune checkpoint receptor ligands.Illustrative immune checkpoint molecules that may be targeted forblocking or inhibition include, but are not limited to, CTLA-4, 4-1BB(CD137), 4-1BBL (CD137L), PDL1, PDL2, PD1, B7-H3, B7-H4, BTLA, HVEM,TIM3, GAL9, LAG3, TIM3, B7H3, B7H4, VISTA, KIR, 2B4 (belongs to the CD2family of molecules and is expressed on all NK, γδ, and memory CD8⁺ (αβ)T cells), CD160 (also referred to as BY55) and CGEN-15049. Immunecheckpoint inhibitors include antibodies, or antigen binding fragmentsthereof, or other binding proteins, that bind to and block or inhibitthe activity of one or more of CTLA-4, PDL1, PDL2, PD1, B7-H3, B7-H4,BTLA, HVEM, TIM3, GAL9, LAG3, TIM3, B7H3, B7H4, VISTA, KIR, 2B4, CD160and CGEN-15049. Illustrative immune checkpoint inhibitors includeTremelimumab (CTLA-4 blocking antibody), anti-OX40, PD-L1 monoclonalAntibody (Anti-B7-H1; MEDI4736), MK-3475 (PD-1 blocker), Nivolumab(anti-PD1 antibody), CT-011 (anti-PD1 antibody), BY55 monoclonalantibody, AMP224 (anti-PDL1 antibody), BMS-936559 (anti-PDL1 antibody),MPLDL3280A (anti-PDL1 antibody), MSB0010718C (anti-PDL1 antibody) andYervoy/ipilimumab (anti-CTLA-4 checkpoint inhibitor).

In a further embodiment, the GLA compositions herein are administered incombination with other TLR4 agonists, or a TLR8 agonist, or a TLR9agonist. Such an agonist may be selected from peptidoglycan, polyI:C,CpG, 3M003, flagellin, and Leishmania homolog of eukaryotic ribosomalelongation and initiation factor 4a (LeIF).

In an additional embodiment, the GLA compositions herein areadministered in combination with a cytokine. By “cytokine” is meant ageneric term for proteins released by one cell population that act onanother cell as intercellular mediators. Examples of such cytokines arelymphokines, monokines, and traditional polypeptide hormones. Includedamong the cytokines are growth hormones such as human growth hormone,N-methionyl human growth hormone, and bovine growth hormone; parathyroidhormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin;glycoprotein hormones such as follicle stimulating hormone (FSH),thyroid stimulating hormone (TSH), and luteinizing hormone (LH); hepaticgrowth factor; fibroblast growth factor; prolactin; placental lactogen;tumor necrosis factor-alpha and -beta; mullerian-inhibiting substance;mouse gonadotropin-associated peptide; inhibin; activin; vascularendothelial growth factor; integrin; thrombopoietin (TPO); nerve growthfactors such as NGF-beta; platelet-growth factor; transforming growthfactors (TGFs) such as TGF-alpha and TGF-beta; insulin-like growthfactor-I and -II; erythropoietin (EPO); osteoinductive factors;interferons such as interferon-alpha, beta, and -gamma; colonystimulating factors (CSFs) such as macrophage-CSF (M-CSF);granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF);interleukins (ILs) such as IL-1, IL-1alpha, IL-2, IL-3, IL-4, IL-5,IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12; IL-15, a tumor necrosisfactor such as TNF-alpha or TNF-beta; and other polypeptide factorsincluding LIF and kit ligand (KL). As used herein, the term cytokineincludes proteins from natural sources or from recombinant cell culture,and biologically active equivalents of the native sequence cytokines.

In certain embodiments, the compositions comprising GLA as describedherein may be administered in combination with chloroquine, alysosomotropic agent that prevents endosomal acidification and whichinhibits autophagy induced by tumor cells to survive accelerated cellgrowth and nutrient deprivation. More generally, the compositionscomprising GLA as described herein may be administered in combinationwith therapeutic agents that act as autophagy inhibitors, radiosensitizers or chemo sensitizers, such as chloroquine, misonidazole,metronidazole, and hypoxic cytotoxins, such as tirapazamine. In thisregard, such combinations of a GLA with chloroquine or other radio orchemo sensitizer, or autophagy inhibitor, can be used in furthercombination with other cancer therapeutic agents or with radiationtherapy.

In another embodiment, the compositions comprising GLA as describedherein may be administered in combination with small molecule drugswhich are known to result in killing of tumor cells with concomitantactivation of immune responses, termed “immunogenic cell death”, such ascyclophosphamide, doxorubicin, oxaliplatin and mitoxantrone.Furthermore, combinations with drugs known to enhance the immunogenicityof tumor cells such as patupilone (epothilone B), epidermal-growthfactor receptor (EGFR)-targeting monoclonal antibody 7A7.27, histonedeacetylase inhibitors (e.g., vorinostat, romidepsin, panobinostat,belinostat, and entinostat), the n3-polyunsaturated fatty aciddocosahexaenoic acid, furthermore proteasome inhibitors (e.g.bortezomib), shikonin (the major constituent of the root of Lithospermumerythrorhizon,) and oncolytic viruses, such as TVec (talimogenelaherparepvec). In other embodiments, the compositions comprising GLA asdescribed herein may be administered in combination with epigenetictherapies, such as DNA methyltransferase inhibitors (e.g. Decitabine,5-aza-2′-deoxycytidine) which may be administered locally orsystemically.

In another embodiment, the compositions comprising a GLA as describedherein may be administered in combination with one or more antibodiesthat increase ADCC uptake of tumor by DCs. Thus, the present inventioncontemplates combining compositions comprising a GLA with any moleculethat induces or enhances the ingestion of a tumor cell or its fragmentsby an antigen presenting cell and subsequent presentation of tumorantigens to the immune system. These molecules include agents thatinduce receptor binding (such as Fc or mannose receptors) and transportinto the antigen presenting cell such as antibodies, antibody-likemolecules, multi-specific multivalent molecules and polymers. Suchmolecules may either be administered intratumorally with the compositioncomprising GLA, or administered by a different route. For example, acomposition comprising GLA as described herein may be administeredintratumorally in conjunction with intratumoral injection of rituximab,cetuximab, trastuzumab, Campath, panitumumab, ofatumumab, brentuximab,pertuzumab, Ado-trastuzumab emtansine, Obinutuzumab, anti-HER1, -HER2,or -HER3 antibodies (e.g., MEHD7945A; MM-111; MM-151; MM-121; AMG888),anti-EGFR antibodies (e.g. Nimotuzumab, ABT-806), or other likeantibodies. Any multivalent scaffold that is capable of engaging Fcreceptors and other receptors that can induce internalization may beused in the combination therapies described herein—e.g. peptides and/orproteins capable of binding targets that are linked to Fc fragments orpolymers capable of engaging receptors.

In certain embodiments, the combination of GLA with such antibodies maybe further combined with an antibody that promotes a co-stimulatorysignal (e.g., by blocking inhibitory pathways), such as anti-CTLA-4, orthat activates co-stimulatory pathways such as an anti-CD40, anti-CD28,anti-ICOS, anti-OX40, anti-CD27 antibodies and the like.

The compositions comprising GLA may be administered alone or incombination with other known cancer treatments, such as radiationtherapy, immune checkpoint inhibitors, chemotherapy or other cancertherapeutic agents, transplantation, immunotherapy, hormone therapy,photodynamic therapy, etc. The compositions may also be administered incombination with antibiotics.

The present disclosure relates to the discovery that GLA can be used asa monotherapy (e.g., not as a vaccine adjuvant) for the treatment ofcancer. Thus, the present disclosure provides a method of treating amammal who suffers from cancer comprising administering an effectiveamount of a composition comprising GLA, wherein the composition does notcomprise an antigen (e.g., does not comprise a tumor antigen). Accordingto the present disclosure, the phrase “does not comprise an antigen” or“does not comprise antigen” refers to a composition that does notinclude an antigen for the purpose of eliciting an antigen-specificimmune response. To that end, a composition that is substantially devoidof antigen or a composition that includes a trace amount of antigen iscontemplated according to the present disclosure, so long as the amountof antigen present is insufficient to elicit a specific immune responseto that antigen.

The GLA compositions described herein may be useful for the treatment ofa variety of cancers. In one embodiment, the compositions comprising aGLA as described herein, wherein the composition does not comprise anantigen, may be useful for the treatment of a variety of solid tumors,i.e., carcinomas, sarcomas, and lymphomas. In certain embodiments, thecancer is a primary solid tumor, and in certain other embodiments acancer is a metastatic or secondary solid tumor. In certain relatedembodiments, the cancer is selected from melanoma, lung cancer, cervicalcancer, ovarian cancer, uterine cancer, breast cancer, liver cancer,gastric cancer, colon cancer, prostate cancer, pancreatic cancer, kidneycancer, bladder cancer, brain cancer, fibrosarcoma, myxosarcoma,liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma,endotheliosarcoma, lymphangiosarcoma, pseudomyxoma petitonei,lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor,leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer,squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, Merkelcell carcinoma, sweat gland carcinoma, sebaceous gland carcinoma,papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma,medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma,hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonalcarcinoma and Wilms' tumor. In certain other related embodiments thecancer cell originates in a cancer that is selected from testiculartumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma,epithelial carcinoma, glioma, glioblastoma multiforme, astrocytoma,plasmocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma,hemangioblastoma, acoustic neuroma, oliodendroglioma, meningioma,melanoma, neuroblastoma, retinoblastoma, leukemia, lymphoma,non-Hodgkin's lymphoma, multiple myeloma, Waldenstrom'smacroglobulinemia or other cancers. Thus, the methods described hereininclude methods for the treatment of, ameliorating the symptoms of, andinhibiting metastasis of cancer comprising administering an effectiveamount of a composition comprising a GLA as described herein, whereinthe composition does not comprise an antigen. As described herein, themethods described herein include methods for the treatment of,ameliorating the symptoms of, and inhibiting metastasis of cancercomprising administering an effective amount of a composition comprisinga GLA as described herein, wherein the composition does not comprise anantigen, in combination with a therapeutically effective amount of oneor more other therapeutic agents. In one embodiment, the methods hereincomprise a method of treating a cancer comprising administering acomposition comprising a GLA wherein the composition does not comprisean antigen, and a composition comprising a checkpoint inhibitor or anantibody that stimulates a co-stimulatory pathway. In one embodiment,the method involves intratumoral injection of the composition comprisingGLA, wherein the composition does not comprise an antigen, andco-administering intratumorally, one or more other therapeutic agents,such as a checkpoint inhibitor or an antibody that stimulates aco-stimulatory pathway (e.g., anti-CD40 antibodies). In one embodimentof the method, the GLA composition and the therapeutic agent, e.g., acheckpoint inhibitor, are administered at the same time. In anotherembodiment of the method, the GLA composition and the therapeutic agent,e.g., a checkpoint inhibitor, antibody that stimulates a co-stimulatorypathway, cytokine or other therapeutic agent, are administeredintratumorally at a separate time, where e.g., the checkpoint inhibitoris administered either before or after injection of the GLA composition.In a further embodiment, the method involves intratumoral injection ofthe composition comprising GLA, without antigen, and administering thetherapeutic agent such as, but not limited to, a checkpoint inhibitor oranti-CD40 antibody, at about the same time but by a different route(e.g., intraperitoneally, i.v., i.m.). Thus, in certain embodiments ofthe present invention, the GLA compositions and other therapeutic agent,such as but not limited to, checkpoint inhibitor or anti-CD40 antibodycompositions, may be administered concurrently or sequentially in anyorder and may be administered at the same site by the same route or maybe administered at different sites by different routes.

Kits may contain one or more doses of GLA compositions, optionally in acontainer such as a vial or blister or capsule or pre-filled syringe,and optionally one or more other therapeutic agents. A kit may alsocontain instructions. Instructions typically describe methods foradministration, including methods for determining the proper state ofthe subject, the proper dosage amount, and the proper administrationmethod, for administering the composition. Instructions can also includeguidance for monitoring the subject over the duration of the treatmenttime.

Kits provided herein also can include devices for administration of eachof the compositions described herein to a subject. Any of a variety ofdevices known in the art for administering medications can be includedin the kits provided herein. Exemplary devices include, but are notlimited to, a hypodermic needle, an intravenous needle, microneedle, acatheter, a needle-less injection device, an aerosolizer, inhaler ornebulizer or atomizer or microspray device, and a liquid dispenser, suchas an eyedropper. Typically, the device for administering a compositionis compatible with the active components of the kit.

Embodiments of the invention include, but are not limited to, thefollowing.

1. A method of treating a mammal who suffers from cancer, comprisingadministering an effective amount of a composition comprising GLA, saidcomposition comprising:

(a) GLA of the formula:

wherein:

R¹, R³, R⁵ and R⁶ are C₁₁-C₂₀ alkyl; and

R² and R⁴ are C₁₂-C₂₀ alkyl; and

(b) a pharmaceutically acceptable carrier or excipient;

wherein the composition does not comprise antigen.

2. An effective amount of a composition comprising GLA, said compositioncomprising:

(a) GLA of the formula:

wherein:

R¹, R³, R⁵ and R⁶ are C₁₁-C₂₀ alkyl; and

R² and R⁴ are C₁₂-C₂₀ alkyl; and

(b) a pharmaceutically acceptable carrier or excipient;

wherein the composition does not comprise antigen; for use in thetreatment of a cancer in a mammal

3. The use of an effective amount of a composition comprising GLA, saidcomposition comprising:

(a) GLA of the formula:

wherein:

R¹, R³, R⁵ and R⁶ are C₁₁-C₂₀ alkyl; and

R² and R⁴ are C₁₂-C₂₀ alkyl; and

(b) a pharmaceutically acceptable carrier or excipient;

wherein the composition does not comprise antigen; for the manufactureof a medicament for the treatment of a cancer in a mammal

4. Any of the preceding embodiments, wherein R¹, R³, R⁵ and R⁶ areundecyl and R² and R⁴ are tridecyl.

5. Any of the preceding embodiments, wherein the mammal is human

6. Any of the preceding embodiments, wherein the composition is anaqueous formulation.

7. Any of the preceding embodiments, wherein the composition is in theform of an oil-in-water emulsion, a water-in-oil emulsion, liposome,micellar formulation, or a microparticle.

8. Any of the preceding embodiments, wherein the cancer comprises asolid tumor. In any of the embodiments described herein, the solid tumoris a carcinoma, a sarcoma or a lymphoma. In any of the embodimentsdescribed herein, the solid tumor is a primary or a secondary solidtumor.

9. Any of the preceding embodiments, wherein the cancer is selected fromthe group consisting of, melanoma, Merkel cell carcinoma, lung cancer,cervical cancer, ovarian cancer, uterine cancer, breast cancer, livercancer, gastric cancer, prostate cancer, colon cancer, kidney cancer,bladder cancer, brain cancer, and pancreatic cancer.

10. Any of the preceding embodiments, wherein the composition isadministered by subcutaneous, intradermal, intramuscular, intratumoral,or intravenous injection.

11. Any of the preceding embodiments, wherein the composition isadministered intranasally or intrapulmonary.

12. Any of the preceding embodiments, wherein the composition isadministered in conjunction with one or more additional therapeuticagents or treatments.

13. Embodiment 12, wherein the therapeutic agents is an immunecheckpoint inhibitor.

14. Embodiment 12 or 13, wherein the therapeutic agent is an antibodythat activates a co-stimulatory pathway. An exemplary such antibody isan anti-CD40 antibody.

15. Embodiment 12 or 13, wherein the therapeutic agent is a cancertherapeutic agent such as a chemotherapeutic agent.

16. Embodiment 15 wherein the cancer therapeutic agent is selected fromthe group consisting of taxotere, carboplatin, trastuzumab, epirubicin,cyclophosphamide, cisplatin, docetaxel, doxorubicin, etoposide, 5-FU,gemcitabine, methotrexate, and paclitaxel, mitoxantrone, patupilone(epothilone B), epidermal-growth factor receptor (EGFR)-targetingmonoclonal antibody 7A7.27, histone deacetylase inhibitors (vorinostatand romidepsin), the n3-polyunsaturated fatty acid docosahexaenoic acid,proteasome inhibitors (e.g. bortezomib), shikonin (the major constituentof the root of Lithospermum erythrorhizon,) and oncolytic viruses, suchas TVec (talimogene laherparepvec).

17. Any of the preceding embodiments, further comprising radiationtherapy.

18. Embodiment 12 wherein the one or more additional therapeutictreatments is radiation therapy.

19. Embodiment 19 comprises a method of treating a mammal who suffersfrom a cancer, wherein the cancer comprises a solid tumor, comprisingadministering intratumorally an effective amount of a compositioncomprising GLA, said composition comprising:

(a) GLA of the formula:

wherein:

R¹, R³, R⁵ and R⁶ are undecyl and R² and R⁴ are tridecyl

(b) a pharmaceutically acceptable carrier or excipient;

wherein the composition does not comprise antigen.

20. Embodiment 19, further comprising administering an immune checkpointinhibitor.

21. Embodiment 19 further comprising administering an anti-CD40antibody.

22. Embodiment 19-21, further comprising administering radiationtherapy.

Other embodiments and uses will be apparent to one skilled in the art inlight of the present disclosures. The following examples are providedmerely as illustrative of various embodiments and shall not be construedto limit the invention in any way.

EXAMPLES Example 1 In Vivo Anti Cancer Effect of GLA in a Murine B16Melanoma Model

This Example demonstrates that GLA was effective at reducing tumor sizeand increasing percent survival as compared to saline treatment in amurine B16 melanoma tumor model.

The B16 murine melanoma model is an accepted animal model for both solidtumor formation as well as metastasis (see e.g., Curr Protoc Immunol.2001 May; CHAPTER 20: Unit-20.1. doi:10.1002/0471142735.im2001s39). Inthis study, mice were inoculated subcutaneously with 3×10⁵ B16 cells onDay minus 9 (n=10 per group). Mice were treated with either saline or 5μg GLA-SE i.m. on Day 0, Day 9 and Day 14.

As shown in FIG. 1, GLA-SE treatment reduced tumor size in mice ascompared to saline alone. As shown in FIG. 2, GLA-SE treatment increasedpercent survival in mice relative to saline alone.

Thus, these experiments demonstrate that GLA used alone has ananti-cancer effect in vivo in an accepted animal tumor model, aftercancer has been established, and support the notion that GLA can be usedas a monotherapy for the treatment of cancer.

Example 2 In Vivo Anti Cancer Effect of GLA in a Murine B16 MelanomaModel

Confirmatory experiments are performed using the B16 model as detailedbelow to further confirm whether GLA-SE administration diminishes B16F10tumor growth in C57BL/6 mice. The B16 footpad melanoma model iswell-established in the field. Tumor growth in the footpad is easilymonitored because B16 melanoma cells are black. This model wasestablished as shown in FIG. 3. In brief, high (1E6) or low (1E5) dosesof B16F10 cells are injected as detailed further below into footpads of8 wk/old C57BL/6J female mice. GLA-SE (5 μg/2% oil) is injected byvarious routes every 3 days, until mice are sacrificed (as tumor areareaches 100 mm²)

Methods:

(Day −4): Culture B16F10 cells; Thaw cryopreserved cells in 37° C. waterbath; B16F10 stock, 1 vial: B16-F10 ATCC Lot #59123188; count cells andseed @ 2-3E6 cells/T225 flask→Incubate @ 37° C., 5% CO2.

(Day 0): Harvest cells; Use cells in logarithmic growth phase (˜50%confluent: 10-12E6 cells/T225 flask); Trypsinize and resuspend cells inappropriate volume of HBSS for doses outlined in Table 1 (generally notto exceed 50 ul volume); Transport harvested cells on ice to vivarium

(Day 0): Inoculate mice; Mice: C57BL/6J females (8½ wk/old atinjection). Anesthetize mice; ear punch mice for identification; inject,s.c., dose of cells as outlined in Table 1, per left mouse footpad;Return mice to cage.

(Day 0+3, onward): Administer GLA-SE or vehicle control (2% oil);Anesthetize mice; Inject GLA-SE (5 μg/2% oil) or vehicle control, s.c.,into left mouse footpads (same footpads where the tumor cells wereinoculated) or i.m. in thigh or s.c. at tail base; Return mice to cage.

Tumor growth is recorded 2-3 times per week. Mice are sacrificed via CO2asphyxiation when tumors reach 100 mm²

The treatment groups for the experiment are outlined in Table 1 below:

TABLE 1 Treatment Groups Tumor Tumor Vaccine Challenge Tumor Dose PrimeVaccine Vaccine Dose Group Mouse # (Day) Type (Cells) (Day)/route Type(ug/% oil) 037-Vehicle-1  1-10 0 B16F10 1.0E5 Every 3 d/foot pad Vehicle(2% oil) 0 037-GLA-1 11-20 0 B16F10 1.0E5 Every 3 d/foot pad GLA-SE 5.0037-Vehicle-2 21-30 0 B16F10 1.0E6 Every 3 d/foot pad Vehicle (2% oil) 0037-GLA-2 31-40 0 B16F10 1.0E6 Every 3 d/foot pad GLA-SE 5.0037-Vehicle-3 41-50 0 B16F10 1.0E5 Every 3 d/i.m. Vehicle (2% oil) 0037-GLA-3 51-60 0 B16F10 1.0E5 Every 3 d/i.m. GLA-SE 5.0 037-Vehicle-461-70 0 B16F10 1.0E6 Every 3 d/i.m. Vehicle (2% oil) 0 037-GLA-4 71-80 0B16F10 1.0E6 Every 3 d/i.m. GLA-SE 5.0 037-Vehicle-5 81-90 0 B16F101.0E5 Every 3 d/s.c, distal site (tail) Vehicle (2% oil) 0 037-GLA-5 91-100 0 B16F10 1.0E5 Every 3 d/s.c, distal site (tail) GLA-SE 5.0037-Vehicle-6 101-110 0 B16F10 1.0E6 Every 3 d/s.c, distal site (tail)Vehicle (2% oil) 0 037-GLA-6 111-120 0 B16F10 1.0E6 Every 3 d/s.c,distal site (tail) GLA-SE 5.0

Additional experiments are performed with GLA injections every other dayor every day. GLA-SE doses and/or formulation may also be modified.

In addition to the above experiments, further confirmatory experimentsand characterization of GLA monotherapy in tumor models are carried outusing a variety of different tumor model systems known to the skilledperson. A variety of subcutaneous xenograft tumor models, orthotopictumor models, metastatic tumor models and syngeneic mouse tumor modelsare used for further characterizing GLA as a monotherapy agent incancer. As non-limiting examples, murine syngeneic model systems usingH22, Hepal-6, P388D1 or S180 are used for evaluating GLA monotherapy inliver, leukemia and sarcoma tumor models. Various metastatic models arealso used for evaluating GLA monotherapy and non-limiting examplesinclude HCCLM3 (liver cancer; stomach and lymph node metastasis), MKN-45(stomach cancer; liver and lymph node metastasis), HT-29 (colon cancer;met liver and lymph node), HCT-116 (colon cancer; met liver and lymphnode), and PC-3 (prostate cancer; met bone). A variety of such animalmodels are commercially available, for example, from GenScript(Piscataway, N.J.) or Charles River Laboratories (Wilmington, Mass.).Additional models suitable for testing include, but are not limited to,models of melanoma, lung cancer, cervical cancer, ovarian cancer,uterine cancer, breast cancer, liver cancer, gastric cancer, prostatecancer, colon cancer, kidney cancer, bladder cancer, brain cancer,pancreatic cancer, leukemia and lymphoma.

In such models, tumor cells are inoculated by the appropriate route(e.g., s.c, i.v. or other route as generally accepted in the model) withestablished dosage of cells. GLA-SE is inoculated i.m. daily, everyother day, every third day, once weekly or every other week Saline canbe used as a control. In certain cases, it may be desirable to use SE asan additional control. Tumor growth and spread to local lymph nodes isassessed. The effect of GLA-SE on PBMCs are assessed for activationstatus by measuring cell surface markers on lymphocytes such as CD26,CD27, CD30, CDw137 (4-1BB), CD152 (CTLA-4), CD154 (gp39), CD134 (OX-40),CD95L (Fas ligand), CD45R/B220, and Ly-6E (TSA, sca-2) and/or cytokineexpression levels such as IL-2, IFN-γ, IL-17, IL-4, IL-13, IL-10.

Example 3 In Vivo Anti Cancer Effect of GLA in a Murine B16 MelanomaModel

Additional experiments were carried out to confirm and furthercharacterize the anti-cancer effect of GLA in a murine B16 melanomamodel.

Mice (n=10 per group) were inoculated into the flank with 5×10⁶ B16F10cells on study day minus 6 (Day −6). Mice were subsequently inoculatedwith either GLA-SE or placebo (saline) on days 0, day 5, day 15, and day24. Tumor size of individual mice was measured every third day. Survivalof mice, as measured by euthanasia when tumor size reached 400 mm² orwhen the tumor developed lesions, was also compared. Results of thisstudy demonstrate that mice treated therapeutically with GLA-SE hadsignificantly reduced tumor size (p>0.008) with clear differencesbetween the groups observed at day 10 (FIG. 4). Mice treated with GLA-SEalso had significantly (p>0.03) increased survival time with cleardifferences between groups observed after day 17 (FIG. 5).

Example 4 In Vivo Anti Cancer Effect of GLA in Murine Tumor Models

This Example demonstrates that GLA is effective at delaying tumor growthas compared to vehicle treatment in certain murine tumor models. Thetumor models tested were B16 melanoma, CT26 colon cancer, 4T1 breastcancer, and P815 mastocytoma.

In this study, on Day 0, the following groups of mice (n=5 per group)were inoculated with the corresponding number of tumor cells: C57BL/6,5×10⁵ B16F10 cells, subcutaneously in the right footpad; BALB/c, 5×10⁵CT26 cells, subcutaneously in the right footpad; BALB/c, 1×10⁵ 4T1 cellsin the 4^(th) right mammary fat pad; DBA/2, 1×10⁴ P815 cells,subcutaneously in the right flank. Mice were given intramuscular (i.m.)or intratumoral (i.t.) administrations of vehicle control (2% SE) or 5μg GLA-SE/2% SE starting on Day 4 and every 3-4 days thereafter untilthe end of study.

As shown in FIG. 6, i.t. administration of GLA-SE delayed tumor growthin mice in multiple murine cancer models more effectively than i.m.administration. Intratumoral administration of GLA-SE delayed B16F10 andP815 tumor growth in a statistically significant manner as compared tovehicle alone. Intratumoral administration of GLA-SE also delayed 4T1tumor growth although this was not statistically significant.Intratumoral injection was more effective than i.m. in these three tumormodels. While i.m. administration of GLA-SE exhibited no effect onB16F10 tumor growth, it slightly delayed both 4T1 and P815 tumor growth.GLA-SE administered i.t. or i.m. exhibited no effect on CT26 tumorgrowth.

The above data demonstrate that GLA as a single agent has astatistically significant anti-cancer effect in vivo in accepted animaltumor models, after cancer has been established, and support the notionthat GLA can be used as a monotherapy for the treatment of cancer.

Example 5 In Vivo Anti Cancer Effect of GLA in Combination withCheckpoint Inhibitors in the B16F10 Murine Tumor Model

This example demonstrates that the addition of certain immune checkpointinhibitors (CPIs) in the presence of GLA further delayed tumor growth ascompared to vehicle treatment.

To determine the optimal time to begin GLA administration, femaleC57BL/6 mice (n=5 per group) were inoculated with 5×10⁵ B16F10 cells,subcutaneously in the right footpad on Day 0. Mice were givenintratumoral (i.t.) administrations of 5 μg GLA-SE/2% SE (or 2% SEvehicle control) on Day 4, Day 9, or Day 14, and every 3-4 daysthereafter until the end of study. When GLA administration began within4 days (but not 9 or 14 days) post-tumor injection, it delayed B16F10tumor growth in mice (FIG. 7A).

To determine whether the addition of a CPI further delayed tumor growth,female C57B1/6 mice (n=5 per group) were inoculated with 5×10⁵ B16F10cells, subcutaneously in the right footpad on Day 0. Mice were giveni.t. administrations of 5 μg GLA-SE/2% SE (or 2% SE vehicle control)plus intraperitoneal (i.p.) administrations of a CPI [anti-PDL1,anti-PD1, anti-CTLA4 (clone 9H10), anti-CTLA4 (clone 9D9), or LTF2control antibody] at 100 μg starting on Day 4 and every 3-4 daysthereafter until the end of study. GLA alone delayed B16F10 tumor growthin mice (FIG. 7B). The addition of anti-PDL1, anti-PD1 (p=0.03), oranti-CTLA4 (clone 9D9; p=0.005) in the presence of GLA further delayedtumor growth as compared to SE vehicle alone. Anti-CTLA4 (clone 9H10)exhibited no additive effect on B16F10 tumor growth, while clone 9D9exhibited therapeutic effect on its own, suggesting therapeutic efficacyvaries between different antibody clones.

The above data demonstrate that the addition of an immune checkpointinhibitor in the presence of GLA statistically significantly enhancesthe overall anti-tumor effect in vivo.

Example 6 In Vivo Anti Cancer Effect of GLA in Combination with theAnti-CD40 Co-Stimulatory Antibody in the B16F10 Murine Tumor Model

This example demonstrates that the addition of anti-CD40 in the presenceof GLA further delayed tumor growth as compared to vehicle treatment.

CD40 is expressed on antigen-presenting cells and is an importantco-stimulatory molecule for the activation of T cells, B cells,dendritic cells, and macrophages. Anti-CD40 has previously been shown toexhibit anti-tumor effects via activation of the innate immuneresponses, such as mobilizing macrophages (Buhtoiarov I N, et al. JImmunother 2005; 174:6013-6022).

To determine whether the addition of anti-CD40 further delayed tumorgrowth, female C57B1/6 mice (n=5 per group) were inoculated with 5×10⁵B16F10 cells, subcutaneously in the right footpad on Day 0. Mice weregiven i.t. administrations of 5 μg GLA-SE/2% SE (or 2% SE vehiclecontrol) plus i.p. administrations of anti-CD40 (or 2A3 controlantibody) at 100 μg, starting on Day 4 and every 3-4 days thereafteruntil the end of study (FIG. 8A). Either GLA or anti-CD40 alone delayedB16F10 tumor growth in mice. The combination of GLA and anti-CD40further delayed tumor growth and the delay was statistically significantas compared to GLA-SE with control antibody as well as compared to SEcontrol.

To determine whether anti-CD40 exerted anti-tumor effects in the tumormicroenvironment, tumor-bearing mice were given i.t. administrations of2 μg GLA-SE/2% SE (or 2% SE vehicle control) on Day 8 and 15 post-tumorinjection and i.t. administrations of 50 μg anti-CD40 (or 2A3 controlantibody) on Day 5 and 12 post-tumor injection (FIG. 8B). Suboptimaldoses for GLA and anti-CD40 were given to avoid masking of a possiblesynergistic effect of the combination. Although either GLA or anti-CD40alone delayed tumor growth, the combination of GLA and anti-CD40, wheninjected locally into the tumor, did not further delay the growth. Thedifferences in therapeutic efficacy observed between i.p. and i.t.administrations of anti-CD40 suggest 1) therapeutic regimen or 2)targeting of systemic or local activation of innate immune response maybe key factors to inducing anti-tumor effects.

The above data demonstrate that the systemic addition of anti-CD40(i.p.) statistically significantly enhances the anti-tumor effect ofintratumorally applied GLA in vivo.

Example 7 In Vivo Anti Cancer Effect of Intratumoral Injection of GLA-SEin Merkel Cell Carcinoma in Human Patients

This Example describes preliminary observations from the first humanpatients dosed with intratumoral GLA-SE.

Merkel cell carcinoma (MCC) is a rare but highly aggressive skin cancerwith a much higher mortality rate than malignant melanoma. Despite theuse of surgery or radiation for patients with loco-regional MCC,recurrence rates are high and there is no established adjuvant therapy.Merkel cell polyomavirus (MCPyV) is a common virus present in eight outof ten MCCs and is thought to be involved in the etiology of thedisease.

Three MCC patients have been treated as part of a Phase I clinical trialentitled, “A Proof of Concept Clinical Trial of Intratumoral Injectionof GLA-SE in Patients with Merkel Cell Carcinoma.” Patients included inthe study had biopsy-confirmed Merkel cell carcinoma with metastatic orloco-regional disease. Patients had to have at least one injectablelesion, defined as an easily palpable superficial lesion (cutaneous,subcutaneous or lymph nodal) that can be accurately localized,stabilized by palpation, and is superficial enough to enableintratumoral (i.t.) injection. Following enrollment, patients wereinjected with 5 ug GLA-SE (1 mL) directly into the tumor(s) two to threetimes, as detailed in the protocol.

One patient with loco-regional disease received 2 doses of GLA-SE ondays 1 and 8 i.t. in a femoral lymph node. Surprisingly, at surgicalresection on day 21, the patient was found to have completely respondedin the treated tumor with no evidence of cancer by pathologic review ofthe excised lesion. Initial observations indicate an enrichment of tumorinfiltrating lymphocytes (TILs). As part of standard of care, thepatient will be receiving post-surgical adjuvant radiation therapy.

Two other patients who presented with metastatic disease were alsotreated. One had no apparent response and disease progressed during thefirst cycle. This patient is now off study. The other patient alsopresented with metastatic disease and had inflammation at the two sitesof injection after the third dose. No information about a non-injectedlesion was provided and no additional information is yet available forthis patient.

This Example describes for the first time, results in humans from aPhase I clinical trial investigating i.t. injection of GLA in theabsence of exogenous antigen. It was entirely unexpected to see acomplete response in this type of cancer that has historically been soresistant to treatment. Although these results are preliminary and theprimary response is an observation in a single patient, they suggestthat GLA-SE injected i.t. has an anti-cancer effect and further supportthe notion that GLA can be used without antigen for the treatment ofcancer.

Example 8 Intratumoral GLA, Anti-CTLA-4 and Rituximab for the Treatmentof Follicular Low Grade NHL

This Example describes the investigation of the effect of GLA incombination with anti-CTLA4 and rituximab antibodies for the treatmentof cancer.

Patients are treated at a single tumor site with intratumoral injectionof GLA, anti-CTLA-4 and rituximab at a dose repeated every weak for 8-10weeks. Two different dose levels are examined. A Phase II trial isconducted for randomized investigation of low versus high dose of GLAwith fixed doses of anti-CTLA4 and rituximab. Staging studies areconducted at baseline and weekly for eight weeks. Endpoints includedirect response at the injected site, abscopal response distally,overall response (complete responses/partial response), time toprogression/progression free survival and time to next treatment.

These studies will test whether the combination of GLA with anti-CTLA4antibodies and antibodies that increase ADCC uptake of tumor antigens indendritic cells or other antigen presenting cells (e.g., rituximab)enhances the anti-tumor immune response and provides therapeutic benefitfor cancer patients.

The various embodiments described above can be combined to providefurther embodiments. All U.S. patents, U.S. patent applicationpublications, U.S. patent application, foreign patents, foreign patentapplication and non-patent publications referred to in thisspecification and/or listed in the Application Data Sheet areincorporated herein by reference, in their entirety. Aspects of theembodiments can be modified if necessary to employ concepts of thevarious patents, applications, and publications to provide yet furtherembodiments.

These and other changes can be made to the embodiments in light of theabove-detailed description. In general, in the following claims, theterms used should not be construed to limit the claims to the specificembodiments disclosed in the specification and the claims, but should beconstrued to include all possible embodiments along with the full scopeof equivalents to which such claims are entitled. Accordingly, theclaims are not limited by the disclosure.

What is claimed is:
 1. A method of treating a mammal who suffers fromcancer, comprising administering an effective amount of a compositioncomprising GLA, said composition comprising: (a) GLA of the formula:

wherein: R¹, R³, R⁵ and R⁶ are C₁₁-C₂₀ alkyl; and R² and R⁴ are C₁₂-C₂₀alkyl; and (b) a pharmaceutically acceptable carrier or excipient;wherein the composition does not comprise antigen.
 2. The method ofclaim 1 wherein R¹, R³, R⁵ and R⁶ are undecyl and R² and R⁴ aretridecyl.
 3. The method of any of claim 1 or 2 wherein the mammal ishuman.
 4. The method of any of claims 1-3, wherein the composition is anaqueous formulation.
 5. The method of any of claims 1-3, wherein thecomposition is in the form of an oil-in-water emulsion, a water-in-oilemulsion, liposome, micellar formulation, or a microparticle.
 6. Themethod of any of claims 1-5, wherein the cancer comprises a solid tumor.7. The method of claim 6, wherein the solid tumor is a carcinoma, asarcoma or a lymphoma.
 8. The method of claim 6, wherein the solid tumoris a primary solid tumor.
 9. The method of claim 6, wherein the solidtumor is a secondary solid tumor.
 10. The method of any of claims 1-5,wherein the cancer is selected from the group consisting of, melanoma,Merkel cell carcinoma, lung cancer, cervical cancer, ovarian cancer,uterine cancer, breast cancer, liver cancer, gastric cancer, prostatecancer, colon cancer, kidney cancer, bladder cancer, brain cancer, andpancreatic cancer.
 11. The method of any of claims 1-10, wherein thecomposition is administered by subcutaneous, intradermal, intramuscular,intratumoral, or intravenous injection.
 12. The method of any of claims1-10, wherein the composition is administered intranasally orintrapulmonary.
 13. The method of any of claims 1-12, wherein thecomposition is administered in conjunction with one or more additionaltherapeutic agents or treatments.
 14. The method of claim 13, whereinthe therapeutic agents is an immune checkpoint inhibitor.
 15. The methodof claim 13, wherein the therapeutic agent is an antibody that activatesa co-stimulatory pathway.
 16. The method of claim 15, wherein theantibody is an anti-CD40 antibody.
 17. The method of claim 13, whereinthe therapeutic agent is a cancer therapeutic agent.
 18. The method ofclaim 17, wherein the cancer therapeutic agent is selected from thegroup consisting of taxotere, carboplatin, trastuzumab, epirubicin,cyclophosphamide, cisplatin, docetaxel, doxorubicin, etoposide, 5-FU,gemcitabine, methotrexate, and paclitaxel, mitoxantrone, epothilone B,epidermal-growth factor receptor (EGFR)-targeting monoclonal antibody7A7.27, vorinostat, romidepsin, docosahexaenoic acid, bortezomib,shikonin and an oncolytic virus.
 19. The method of claim 13 wherein theone or more additional therapeutic treatments is radiation therapy.